[23]
The applicants are entitled to sufficient information to define the issues at a very early stage. There is sufficient material in the NDS to meet the requirements of Division 8 of the
Food and Drug Regulations
at ss. C.08.002-C.08.004. The patent is a patent for a product made by a process. Nu-Pharm has conceded that is the proper name under s. 2.1.1. The source has been disclosed to the applicants under s. 2.1.2. Nu-Pharm advises that the supplier is consistent throughout the relevant period. The flow sheet for manufacturing process has been disclosed to the applicants. There was no evidence before me from an expert to say why the conditions and quality control checks are required.